After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
Stocks Info
Acadia Pharmaceuticals Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Acadia Pharmaceuticals Inc is $4.24B. A total of 0.56 million shares were traded on the day, compared to an average of 2.00M shares.
In the most recent transaction, Schneyer Mark C. sold 10,262 shares of ACAD for 23.69 per share on Nov 18 ’25. After the transaction, the EVP, CHIEF FINANCIAL OFFICER now owns 53,338 company shares. In a previous transaction on Nov 18 ’25, Kihara James sold 4,084 shares at 23.69 per share. ACAD shares that PRINCIPAL ACCOUNTING OFFICER owns now total 25,058.
Among the insiders who sold shares, Daly James M disposed of 30,000 shares on Nov 10 ’25 at a per-share price of $22.37. This resulted in the Director holding 4,041 shares of ACAD after the transaction. In another insider transaction, James M Daly bought 30,000 shares at $22.37 per share on Nov 10 ’25.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, ACAD has a high of $26.65 and a low of $13.40.
As of this writing, ACAD has an earnings estimate of $0.15 per share for the current quarter. EPS was calculated based on a consensus of 14.0 estimates, with a high estimate of $0.23 per share and a lower estimate of $0.1. The company reported an EPS of $0.86 in the last quarter
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. ACAD’s latest balance sheet shows that the firm has $520.71M in Cash & Short Term Investments as of fiscal 2021. There were $64.43M in debt and $96.07M in liabilities at the time. Its Book Value Per Share was $5.42, while its Total Shareholder’s Equity was $540.89M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ACAD is Buy with a score of 4.05.
